Agios Pharmaceuticals AGIO Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Agios Pharmaceuticals's accrued liabilities, current?
- Agios Pharmaceuticals (AGIO) reported accrued liabilities, current of $26.29M in Q1 2026.
- How has Agios Pharmaceuticals's accrued liabilities, current changed year-over-year?
- Agios Pharmaceuticals's accrued liabilities, current increased by 26.6% year-over-year, from $20.76M to $26.29M.
- What is the long-term trend for Agios Pharmaceuticals's accrued liabilities, current?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's accrued liabilities, current has grown at a 8.1% compound annual growth rate (CAGR), from $30.8M to $45.46M.